Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus
Authors
Keywords
-
Journal
CIRCULATION
Volume 142, Issue 22, Pages 2172-2188
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2020-12-01
DOI
10.1161/circulationaha.120.045465
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study
- (2020) Ply Chichareon et al. ATHEROSCLEROSIS
- Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation
- (2020) Dominick J. Angiolillo et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
- (2020) Davide Capodanno et al. Nature Reviews Cardiology
- Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association
- (2020) Suzanne V. Arnold et al. CIRCULATION
- The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial
- (2020) Deepak L. Bhatt et al. CIRCULATION
- Ticagrelor with or without Aspirin in High-Risk Patients with Diabetes Mellitus undergoing Percutaneous Coronary Intervention
- (2020) Dominick J. Angiolillo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis
- (2020) Mauro Chiarito et al. LANCET
- Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y 12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
- (2020) Francesco Franchi et al. Journal of the American Heart Association
- Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial
- (2020) Guillaume Marquis-Gravel et al. JAMA Cardiology
- Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention
- (2020) Francesco Franchi et al. CIRCULATION
- Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y 12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial
- (2019) Francesco Franchi et al. Journal of the American Heart Association
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
- (2019) Donna K. Arnett et al. CIRCULATION
- Modulation of CYP450 activities in patients with type 2 diabetes
- (2019) Sophie Gravel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus
- (2019) Eugenia Gkaliagkousi et al. Diabetes & Vascular Disease Research
- Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials
- (2019) Samuel Seidu et al. Cardiovascular Diabetology
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention
- (2019) Philip Urban et al. CIRCULATION
- Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
- (2019) Dirk Sibbing et al. JACC-Cardiovascular Interventions
- Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention
- (2019) Joo-Yong Hahn et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
- (2019) Hirotoshi Watanabe et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
- (2019) Dominick J. Angiolillo et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
- (2019) Deepak L Bhatt et al. LANCET
- Ticagrelor with or without Aspirin in High-Risk Patients after PCI
- (2019) Roxana Mehran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
- (2019) Stefanie Schüpke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ticagrelor in Patients with Stable Coronary Disease and Diabetes
- (2019) P. Gabriel Steg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
- (2018) Peter M Rothwell et al. LANCET
- Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
- (2018) Davide Capodanno et al. Nature Reviews Cardiology
- Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
- (2018) Pascal Vranckx et al. LANCET
- Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
- (2018) J Michael Gaziano et al. LANCET
- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
- (2018) John J. McNeil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
- (2018) John J. McNeil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus
- (2017) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus
- (2017) Fabiana Rollini et al. THROMBOSIS AND HAEMOSTASIS
- Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status
- (2017) Mark R. Thomas et al. THROMBOSIS AND HAEMOSTASIS
- Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus
- (2017) Zsolt Fejes et al. THROMBOSIS AND HAEMOSTASIS
- Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus
- (2016) Paul A. Gurbel et al. AMERICAN JOURNAL OF CARDIOLOGY
- Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery DiseaseClinical Perspective
- (2016) Francesco Franchi et al. CIRCULATION
- Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy StudyCLINICAL PERSPECTIVE
- (2016) Ian T. Meredith et al. CIRCULATION
- Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus
- (2016) Davide Capodanno et al. CIRCULATION
- Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes MellitusClinical Perspective
- (2016) Yoshihiko Saito et al. CIRCULATION
- Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54
- (2016) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel
- (2015) José M. Cubero Gómez et al. ACTA CARDIOLOGICA
- Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study
- (2015) Dimitrios Alexopoulos et al. Cardiovascular Diabetology
- Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
- (2015) M. A. Cavender et al. CIRCULATION
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
- (2015) Marc P. Bonaca et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microvesicles from platelets: novel drivers of vascular inflammation
- (2015) Tanja Vajen et al. THROMBOSIS AND HAEMOSTASIS
- Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease
- (2014) Dominick J. Angiolillo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Novel antiplatelet agents in acute coronary syndrome
- (2014) Francesco Franchi et al. Nature Reviews Cardiology
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
- (2014) Laura Mauri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity
- (2013) Usman Baber et al. THROMBOSIS AND HAEMOSTASIS
- Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus status
- (2012) Piera Capranzano et al. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
- Drug Resistance and Pseudoresistance
- (2012) Tilo Grosser et al. CIRCULATION
- The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes
- (2012) B. ROCCA et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Vorapaxar in the Secondary Prevention of Atherothrombotic Events
- (2012) David A. Morrow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
- (2011) José Luis Ferreiro et al. CIRCULATION
- Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease
- (2011) Davide Capodanno et al. Circulation-Cardiovascular Interventions
- A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
- (2011) D. J. Angiolillo et al. EUROPEAN HEART JOURNAL
- Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
- (2011) Dominick J. Angiolillo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy
- (2011) Dominick J. Angiolillo et al. THROMBOSIS AND HAEMOSTASIS
- Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications
- (2011) Galia Spectre et al. THROMBOSIS AND HAEMOSTASIS
- The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk
- (2010) Stephen Pratt et al. American Journal of Cardiovascular Drugs
- Low-Dose Aspirin-Induced Ulceration Is Attenuated by Aspirin–Phosphatidylcholine: A Randomized Clinical Trial
- (2010) Byron Cryer et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
- (2010) Stefan James et al. EUROPEAN HEART JOURNAL
- Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy
- (2010) Dominick J. Angiolillo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial)
- (2009) Arijit Dasgupta et al. AMERICAN JOURNAL OF CARDIOLOGY
- Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization
- (2009) Andrew L. Frelinger et al. CIRCULATION
- Platelet thrombin receptor antagonism and atherothrombosis
- (2009) D. J. Angiolillo et al. EUROPEAN HEART JOURNAL
- Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
- (2009) JL Mega et al. LANCET
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- (2009) Lars Wallentin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
- (2008) Stephen D. Wiviott et al. CIRCULATION
- A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
- (2008) D. J. Angiolillo et al. EUROPEAN HEART JOURNAL
- Elevated Plasma Fibrinogen and Diabetes Mellitus Are Associated With Lower Inhibition of Platelet Reactivity With Clopidogrel
- (2008) Lawrence Ang et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo
- (2008) David Erlinge et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients With Diabetes Mellitus
- (2008) Seung-Whan Lee et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Functional variability of platelet response to clopidogrel correlates with P2Y12 receptor occupancy
- (2008) Claire Bal dit Sollier et al. THROMBOSIS AND HAEMOSTASIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started